Prospective Multi-centre Study of Prognostic Factors in Castration-Resitant Prostate Cancer Patients Treated With Radium-223
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Radium 223 chloride (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacodynamics
- Acronyms PRORADIUM
- 05 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 05 Mar 2018 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
- 12 Sep 2017 Recruitment is ongoing at 48 centres and 54 patients have been included, as reported in an abstract presented at the 42nd European Society for Medical Oncology Congress. This trial is funded by Bayer Hispania.